LONDON, June 13, 2014 /PRNewswire/ --
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at:
http://www.investor-edge.com/3742-register
AbbVie Inc.'s stock fell by 1.05% on Thursday, closing the day at $53.66. The stock recorded a trading volume of 3.94 million shares, which was below its three months average volume of 5.76 million shares. The company's shares oscillated between $53.46 and $54.25 during the session. Over the last one month and from the beginning of 2014, AbbVie Inc.'s shares have gained 2.46% and 1.61%, respectively. However, the company's stock has edged lower by 0.33% in the previous three trading sessions. The company's shares are trading above their 50-day and 200-day moving averages. AbbVie Inc.'s 50-day moving average of $51.90 is above its 200-day moving average of $49.72. Furthermore, the company's stock traded at a PE ratio of 18.71 and has a Relative Strength Index (RSI) of 57.14. Sign up today to read free research on ABBV at:
http://www.investor-edge.com/3742-ABBV-13Jun2014.pdf
Shares in AcelRx Pharmaceuticals Inc. recorded a trading volume of 0.68 million shares, above its three months average volume of 0.57 million shares. The stock ended the day at $9.16, which was 1.89% higher its previous day's closing of $8.99, and registered an intraday range of $8.92 and $9.24. Shares in AcelRx Pharmaceuticals Inc. have fallen by 5.66% in the last one month and 19.01% on YTD basis, while the shares have advanced 6.64% in the previous three trading sessions. The company's stock is trading below its 50-day and 200-day moving averages of $9.97 and $10.20, respectively. Further, shares of the company have an RSI of 44.78. Sign up today to read free research on ACRX at:
http://www.investor-edge.com/3742-ACRX-13Jun2014.pdf
On Thursday, shares in Bristol-Myers Squibb Co. fluctuated between $46.71 and $47.45 before ending the session 0.17% lower at $46.88. The company's stock reported a trading volume of 7.20 million shares, which was below its three months average volume of 9.00 million shares. The company's stock traded at a PE ratio of 26.63. Shares in Bristol-Myers Squibb Co. have gained 0.62% in the previous three trading sessions, although, the shares have lost 9.86% in the last one month and 11.80% on YTD basis. Bristol-Myers Squibb Co.'s stock is trading below its 50-day and 200-day moving averages of $49.58 and $50.44, respectively. Additionally, the company's shares have an RSI of 34.49. Sign up today to read free research on BMY at:
http://www.investor-edge.com/3742-BMY-13Jun2014.pdf
Shares in GW Pharmaceuticals PLC finished Thursday's trading session 3.02% higher at $77.40. A total of 0.85 million shares were traded, which was near its three months average volume of 0.88 million shares. The stock moved between $75.27 and $79.24 during the session. SGW Pharmaceuticals PLC's stock has gained 2.80% in the previous three trading sessions and 10.94% in the last one month. Moreover, the company's shares have surged 86.33% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages of $64.32 and $46.12, respectively. Furthermore, GW Pharmaceuticals PLC's stock has an RSI of 64.59. Sign up today to read free research on GWPH at:
http://www.investor-edge.com/3742-GWPH-13Jun2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Investor-Edge.com
SOURCE Investor-Edge
